BiologyarXiv
Heuristic editor, no API keyVerdict: NotableDe novo design of monoclonal and bispecific antibodies with OFAntibody
Recent advances in generative protein design have enabled de novo antibody generation with explicit target and epitope conditioning.
Key numbers
- 5.39-fold improvement over RFantibody in
- 100% across the three evaluated
- 13% and 8% for diabody
Caveats
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
Recent advances in generative protein design have enabled de novo antibody generation with explicit target and epitope conditioning. However, most existing approaches remain formulated around a single antigen-antibody interface, whereas bispecific antibody design requires modeling multi-component complexes in which multiple target-recognition interfaces must coexist and interact within a shared antibody structure. Here we present OFAntibody, an all-atom generative framework for de novo design of monoclonal and bispecific antibodies. OFAntibody expands CDR-epitope interaction learning with large-scale distilled antigen-antibody complexes, and introduces multi-component structural supervision and arm-aware multi-hotspot routing to learn compatible multi-interface geometries and couple each antibody paratope to its designated epitope. OFAntibody supports epitope-conditioned generation across monoclonal antibodies and diverse bispecific formats, including tandem VHH, diabody and CODV. In nanobody design benchmarks, OFAntibody achieves a Top-5 enrichment rate of 41.5%, representing a 5.39-fold improvement over RFantibody in competitive candidate ranking. In bispecific antibody design tasks, OFAntibody achieves hotspot pass rates of 94-100% across the three evaluated tasks and achieves energy pass rates of 60%, 13% and 8% for diabody, tandem VHH and CODV formats, respectively. OFAntibody further enables the same target combination to be explored across different antibody formats, while joint multi-interface generation reduces geometric incompatibilities arising from independent design and post hoc assembly. Together, these results extend de novo antibody design from binary antigen-antibody complexes to programmable multi-component complexes, providing a foundation for designing single molecules that combine recognition of distinct targets and their associated biological functions.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ████░ 4 | 24% | A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing). |
| Magnitude | ███░░ 3 | 16% | Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 20% | A new combination of known ideas. |
| Trajectory | ███░░ 3 | 10% | A clear path to scale. |
| Stakes | ██░░░ 2 | 10% | Benefits a professional community (practitioners, clinicians, engineers). |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose); breadth (many tasks, programmable); gains (x-fold); verification (multiple benchmarks, independent replication); scale (scalable).
How the score was computed
- Merit
- 5.9 / 10
- Adjusted merit
- 4.8 / 10
- Attention
- 0%
- Freshness
- 91%